Business
KRTL Biotech, Inc. Announces Leadership Transition and Strategic Partnerships
KRTL Biotech, Inc. Announces Leadership Transition and Strategic Partnerships.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL Holding Group, Inc. (OTC: KRTL), a holding company with two subsidiaries, is pleased to announce its wholly owned subsidiary KRTL Biotech, Inc., are pleased to announce several significant developments that will shape the future of the organization.First and foremost, the company would like to express its deep appreciation to Daniel Ball, who has served as CEO of KRTL Biotech, Inc. Under his strategic guidance, KRTL Biotech, Inc. has achieved remarkable milestones, including the negotiation of a partnership with a cybersecurity firm, Seven Cipher, a premier veteran-owned company offering AI-powered detection solutions that safeguard cloud, endpoint, and code-level infrastructure. Seven Cipher's extensive background collaborating with Fortune 500 companies, the Department of Defense, and the intelligence community has provided KRTL with customized security and compliance solutions that are at the forward edge of AI-assisted attack mitigation and full spectrum cybersecurity protection. This partnership allows KRTL to offer the Seven Cipher full suite of services as part of a KRTL branded comprehensive technology strategy in the Medtech, alternative medicine, medical device, and other technology sectors.Additionally, Daniel Ball successfully negotiated an exclusive white-label partnership with Medflow, an AI-powered telemedicine solution that integrates advanced facial recognition biometrics within a next-generation zero-trust security architecture. This arrangement enables KRTL to offer accurate verification of patient identities, live heartrate, breathing, and other vital capture without hardware assistance. It further reinforces KRTL’s commitment to leveraging technology to advance quality and efficiency of care in ensure technical and alternative wellness sectors and ensures access to products that can support stakeholder priorities.Mr. Ball’s work in these areas alongside his efforts in establishing exclusive mobile extraction capabilities, international opportunity zone access, and other business development footholds have positioned KRTL with “go-to-market” readiness on multiple fronts. As part of the company's ongoing growth and development, Daniel Ball will be transitioning from his role as CEO to join KRTL Biotech, Inc.'s advisory board. In this capacity, he will lend his expertise to support the company's ongoing an...